Q-omics provides the consensus-scored TRAJ52 profile across patient tissues and cancer cell-line models. TRAJ52 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, TRAJ52 is differentially expressed in 2, with the highest sampling consensus in PAAD. Additionally, TRAJ52 RNA expression shows 10,659 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight COAD, PAAD, and LSCC as cancer lineages where TRAJ52 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRAJ52 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRAJ52 survival associations across molecular data types. TRAJ52 RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRAJ52 RNA expression–survival associations across cancer types. High TRAJ52 expression shows unfavorable associations in COAD, UVM, CHOL, HNSC, LGG and KIRC. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for TRAJ52 RNA expression.
This table summarizes TRAJ52 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in PAAD for RNA.
This table ranks reproducible tumor–normal expression differences for TRAJ52. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRAJ52 shows lower tumor expression in PAAD and higher tumor expression in BRCA. The PAAD box plot shows higher TRAJ52 RNA expression in normal versus tumor tissue (log2 FC = −0.777, t-test p = .028).
This table shows molecular features associated with TRAJ52 in patient tissues and cancer cell lines. In patient samples, TRAJ52 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
